+

WO2010067869A1 - Agent antiviral et composition antivirale - Google Patents

Agent antiviral et composition antivirale Download PDF

Info

Publication number
WO2010067869A1
WO2010067869A1 PCT/JP2009/070764 JP2009070764W WO2010067869A1 WO 2010067869 A1 WO2010067869 A1 WO 2010067869A1 JP 2009070764 W JP2009070764 W JP 2009070764W WO 2010067869 A1 WO2010067869 A1 WO 2010067869A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
antiviral
composition
genus
antiviral agent
Prior art date
Application number
PCT/JP2009/070764
Other languages
English (en)
Japanese (ja)
Inventor
整 島本
泰 冲中
剛正 坂口
徹 辻
義昭 中井
Original Assignee
国立大学法人広島大学
アルタン株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人広島大学, アルタン株式会社 filed Critical 国立大学法人広島大学
Priority to JP2010542138A priority Critical patent/JP5670201B2/ja
Publication of WO2010067869A1 publication Critical patent/WO2010067869A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/44—Ebenaceae (Ebony family), e.g. persimmon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • the present invention relates to human or livestock pathogenic viruses such as enveloped viruses (eg, human influenza virus, avian influenza virus, herpes simplex virus type 1, Newcastle disease virus, vesicular stomatitis virus, viral hemorrhagic septicemia virus, etc. Extract of plants belonging to the genus Oyster which contains tannins, which is highly effective against fish disease virus) and highly safe to human body, catechins, wattle tannins, pentagalloyl glucose, coffee tannins, pyrogallol, gallic acid, pentyl tannins
  • the present invention relates to an antiviral agent as an active ingredient and the like, and an antiviral composition containing the antiviral agent and useful for disinfection of the virus and prevention of infection.
  • viral diseases are difficult to treat because antibiotics and the like do not show an effect, which is a big problem for animals such as humans and livestock.
  • SARS and avian influenza have become a hot topic is a new memory.
  • Viral diseases are also a major problem in cultured fish, but there is no effective treatment, and vaccine prevention is the main countermeasure.
  • compositions containing persimmon astringent or persimmon tannin include, for example, an antibacterial dental composition containing a persimmon astringent extract with cyclodextrin to further improve handling and antibacterial properties (special No. 2005-232043: Patent Document 1), anticancer agent and anti-pneumonia virus agent obtained by further adding astringency to components such as peptide polysaccharides contained in ganoderma spores (Japanese Patent Laid-Open No. 2004-331641: Patent Document 2) Has been proposed.
  • Patent Document 3 describes an antibacterial composition containing a tannin substance, a fatty acid ester, a chelating agent, and the like ([Claim 1]). Examples thereof include tannic acid, pyrocatechin, gallic acid, persimmon tannin, tea tannin, pentaploid tannin and the like ([Claim 4]).
  • tannic acid pyrocatechin, gallic acid
  • persimmon tannin tea tannin
  • pentaploid tannin pentaploid tannin and the like
  • the effectiveness of this antibacterial composition has only been demonstrated against Escherichia coli and Staphylococcus aureus when tannic acid is used ([Example]). There is no specific disclosure that it has significant antiviral properties against envelope viruses, and therefore is extremely useful as a component of antiviral compositions.
  • Patent Document 4 JP-A-2006-306836 (Patent Document 4) describes that a specific phenol derivative is effective as an inactivating agent for various non-enveloped or enveloped viruses.
  • the phenol derivative include gallic acid alkyl esters, (N-propyl gallate, n-octyl gallate, catechin gallate, gallocatechin gallate, epicatechin gallate, etc.) are exemplified.
  • n-octyl gallate has antiviral activity against herpes simplex virus type 1 (HSV-1) and vesicular stomatitis virus (VSV), Whether catechin gallate or the like contained has antiviral activity has not been demonstrated.
  • HSV-1 herpes simplex virus type 1
  • VSV vesicular stomatitis virus
  • Patent Document 5 JP-T-2004-529889 discloses a C1-C3 alcohol (for example, ethanol) or a C2-C4 diol, and an acid (for example) sufficient to adjust the pH of the composition to 4.6 or less.
  • an acid for example
  • a composition containing an organic acid has an inactivating action of envelope virus.
  • the examples specifically show that a solution containing ethanol and hydrochloric acid, glycolic acid or succinic acid has antiviral activity against labial herpesvirus (HSV-1).
  • the present inventors have heretofore used an antiviral agent against norovirus that causes food poisoning and infectious gastroenteritis using an oyster extract and an anti-norovirus composition using the same (PCT / JP2008 / 060705). And an antiviral agent against a non-enveloped virus using an oyster extract and other specific tannins or tannin-like substances and an antiviral composition (PCT / JP2009 / 056635) using the same.
  • Sugiyama et al. Non-patent Document 3 describe that persimmon astringent tannin exhibits a strong anti-norovirus action and the possibility of using it as a disinfectant (ethanol preparation).
  • the present invention relates to an antiviral agent excellent in inactivating action of envelope virus and having high safety to the human body, and an antiviral composition containing this antiviral agent and useful for disinfection and prevention of infection of these viruses.
  • the purpose is to provide.
  • the present inventors have searched for substances and plant components that are recognized as foods or food additives, that is, substances that have antiviral activity from materials that are safe to use in the mouth.
  • tannin-containing extracts of the genus Occumaceae have been found to have significant antiviral activity against a wide range of enveloped viruses, and other tannins or tannin-like substances, citric acid and / or salts thereof are also enveloped.
  • the present invention has been completed by finding that it has antiviral activity against viruses.
  • the outline of the present invention is as follows. [1] Depressing the enzyme derived from the plant of the genus Diospyros contained in the squeezed or extracted liquid of the fruit of the genus Diospyros plant containing tannin by heating or treating with alcohol The antiviral agent with respect to envelope virus which uses the oyster extract processed material obtained by making it an active ingredient. [2] The antiviral agent according to [1], wherein the processed product of oyster extract contains at least condensed tannin. [3] The antiviral agent according to [1] or [2], wherein the plant of the genus Oyster is Diospyros kaki.
  • the antiviral agent in any one.
  • the envelope virus is a human influenza virus, avian influenza virus, vesicular stomatitis virus, herpes simplex virus type 1, Newcastle disease virus, or viral hemorrhagic sepsis virus, according to [5] Antiviral agent.
  • An antiviral alcohol preparation containing at least the antiviral agent according to any one of [1] to [6] and an alcohol.
  • An antiviral cleaning composition comprising at least the antiviral agent according to any one of [1] to [6] and a surfactant.
  • An antiviral disinfecting composition comprising at least the antiviral agent according to any one of [1] to [6] and an antibacterial agent (excluding ethanol, organic acids and salts thereof).
  • the oyster extract processed product (in terms of solid content) in the antiviral agent is contained in a proportion of 0.01 to 5% by weight with respect to the total composition, [7] to [9] The antiviral composition as described.
  • the antiviral composition according to any one of [7] to [10] which contains an organic acid and / or a salt thereof in an amount that results in a pH of the composition of 6.0 to 2.0.
  • the squeezed or extracted liquid of the fruit of the genus Oyster plant is heated or treated with alcohol to thereby contain the plant of the genus Oyster What is obtained by inactivating the enzyme derived from the above (a processed product of oyster extract) is desirable, and one containing at least condensed tannin, for example, one obtained from Diospyros kaki is preferable.
  • the antiviral agent of the present invention includes oyster extracts, catechins (catechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, etc.), wattle, depending on the target envelope virus. Tannin, pentagalloylglucose, coffee tannin, pyrogallol, gallic acid, pentaploid tannin and the like can also be used as active ingredients. Furthermore, an organic acid and / or a salt thereof (excluding those in the oyster extract or a processed product thereof) can also be used as an active ingredient of an antiviral agent. These active ingredients of the antiviral agent may be used singly or in combination.
  • Such an antiviral agent is an active ingredient against an envelope virus of a composition in combination with an alcohol, a surfactant, an antibacterial agent (excluding ethanol, organic acids and salts thereof), a moisturizing agent, cosmetic oils and the like. It is preferred to use.
  • the antiviral composition of the present invention contains the antiviral agent and at least one selected from the group consisting of alcohols, surfactants, antibacterial agents, moisturizers and cosmetic oils and fats.
  • Such an antiviral composition preferably contains the antiviral agent (in terms of solid content) in a proportion of 0.01 to 5% by weight based on the entire composition. It is also preferable to contain an organic acid and / or a salt thereof in such an amount that the pH of the composition is 6.0 to 2.0. Further, the antiviral composition preferably contains vitamin Cs.
  • the antiviral composition of the present invention comprises an antiviral alcohol preparation containing at least the antiviral agent and an alcohol, an antiviral cleaning composition containing at least the antiviral agent and a surfactant, It is provided as an antiviral disinfecting composition containing the antiviral agent and the antibacterial agent.
  • the present invention relates to an envelope virus, such as spraying, applying, etc., to an area where there is a possibility of contamination by the envelope virus, such as an antiviral agent or antiviral composition that is a substance containing the above-described components.
  • an envelope virus such as spraying, applying, etc.
  • an antiviral agent or antiviral composition that is a substance containing the above-described components.
  • the antiviral agent of the present invention can also be used as an active ingredient of a therapeutic or prophylactic agent for infectious diseases caused by enveloped viruses. That is, the therapeutic or preventive agent for infectious diseases against the envelope virus of the present invention is characterized by containing the antiviral agent as an active ingredient.
  • viruses have different structures depending on their types, so the behavior or resistance to chemical substances and chemicals is different for each type, but it is particularly useful for antiviral agents that use at least oyster extract. In that case, it has a feature that it is effective against a wide range of viruses regardless of the type of the virus.
  • antiviral agents are not only substances that can be used alone, but also compositions such as alcohol preparations, cleaning compositions, hand soaps, disinfecting compositions, lotions, emulsions, creams, etc. Alternatively, it is extremely useful as an active ingredient such as pharmaceuticals against enveloped viruses. Then, the antiviral agent of the present invention or the composition containing the antiviral agent of the present invention is attached to the target envelope virus or a place where it may be attached (generally, a non-living body and a living body surface). However, when the composition is a pharmaceutical, it may be in the body of a living body) and used for disinfection or infection prevention.
  • the antiviral composition of the present invention Since oyster extract (oyster tannin) and the like are recognized as food additives, all the components of the antiviral composition of the present invention are composed of food or food additives and adhere to food and tableware. It is possible to obtain a composition that does not cause a problem even if it is consumed.
  • the antiviral composition of the present invention containing such an oyster extract as an active ingredient it is possible to efficiently disinfect envelope viruses and prevent infection in situations where food is handled or in medical institutions. It is expected that the occurrence of diseases caused by these viruses can be greatly suppressed.
  • FIG. 1 shows the antiviral activity of various drugs against human influenza virus in Example 1.
  • FIG. 2 shows the antiviral activity of various drugs against the avian influenza virus in Example 1.
  • FIG. 3 shows the antiviral activity of various drugs against vesicular stomatitis virus in Example 1.
  • FIG. 4 shows the antiviral activity of various drugs against herpes simplex virus type 1 in Example 1.
  • FIG. 5 shows the antiviral activity of various drugs against Newcastle disease virus in Example 1.
  • FIG. 6 shows the antiviral activity of various drugs against avian influenza virus in Example 4.
  • FIG. 7 shows the antiviral activity of various drugs against human influenza virus in Example 5.
  • the antiviral agent and antiviral composition of the present invention can be applied to a wide range of enveloped viruses.
  • the present invention can be applied to various enveloped viruses shown in Table 1, which are known as pathogenic viruses of humans or livestock (mammals and birds).
  • a fish disease virus it can apply to the following various envelope viruses, for example.
  • Rhabdoviridae single-stranded RNA virus, cannonball type Novirhabdoviridae
  • Viral hemorrhagic septicemia virus (Viral hemorrhagic septicemia virus) ... causes viral hemorrhagic sepsis mainly in salmonids in freshwater fish and flounder in marine fish.
  • Herpesviridae double-stranded DNA virus, spherical Ictalurivirus American catfish herpesvirus (Ictalurid herpesvirus 1) ... causative agent of American catfish virus disease / Koi herpesvirus (genus unknown, unclassified) ...
  • koi herpesvirus disease Viruses that have become very problematic in recent years.
  • Roniviridae single-stranded DNA virus, long spherical Okavirus Yellow head virus ... The causative agent of shrimp yellow head disease.
  • Nucleopolyhedrovirus (Nucleopolyhedrovirus) Monodon-type baculovirus (Penaeus monodon NPV): Cause of monodon-type baculovirus infection.
  • the active ingredient of the antiviral agent of the present invention is selected from among oyster extracts, catechins, wattle tannins, pentagalloyl glucose, coffee tannins, pyrogallol, gallic acid, pentaploid tannins, etc., depending on the target envelope virus. Appropriate ones can be selected.
  • an extract of an oyster genus plant containing tannin that is, an oyster extract (sometimes referred to as persimmon shibutannin) is used.
  • this oyster extract may contain the solvent etc. which were used for extracting not only the substance derived from the plant of the genus Oyster which contains tannin.
  • the raw material of the oyster extract is not particularly limited, but it is efficient to use immature fruits of astringents (for example, oyster oysters, varieties such as flat seedless) that are rich in oyster tannins (especially condensed tannins) And economical. Moreover, as long as the oyster extract which consists of a similar component is obtained, it is good also considering a site
  • a method for preparing an oyster extract from such a raw material is not particularly limited, but generally, a method for recovering squeezed juice by pulverizing and compressing an astringent from which cocoons have been removed, or an appropriate size.
  • a method in which the mixture is cut into a liquid and then liquefied by a mixer, and the supernatant is collected by a centrifuge, or a method in which the extract is collected by extraction with water or an aqueous solvent is used.
  • the oyster extract of the present invention squeezed juice or extract of the fruits of the genus Oyster can be used as they are, but those heated or treated with alcohol ( Hereinafter, it is desirable to use “processed oyster extract”.
  • the antiviral properties of the oyster extract are further increased by heating or alcohol treatment, and at the same time, the measurement for verifying the antiviral properties can be prevented from being inhibited.
  • Such a processed product of oyster extract can be prepared relatively easily and has the advantage that color and odor are hardly a problem when used as a component of the composition, and it takes time for fermentation. It is easier to use industrially than amber (see below), which is difficult to use in terms of color and odor. Further, even when stored for a long time by heating or alcohol treatment as described above, no discoloration or precipitation occurs.
  • the temperature and time conditions of the heat treatment may be any conditions that can inactivate enzymes derived from plants belonging to the genus Oyster that are contained in juices, etc., and are generally used to deactivate plant enzymes. Conditions can be adopted. That is, the temperature is usually 60 to 130 ° C., and the time is usually 5 seconds to 30 minutes. For example, the heat treatment is performed at 120 ° C. to 130 ° C. for 5 to 10 seconds, or at about 85 ° C. for 5 to 15 minutes. Just do it.
  • the aspect of a heat processing process is not specifically limited, For example, the heating in the process which sterilizes juice, the heating in the process which pulverizes, or before the fermentation start for manufacturing a persimmon astringent (details are mentioned later)
  • the treatment can be performed by heating or the like.
  • the alcohol treatment can be usually performed using 30-100%, preferably 50-100% alcohol such as ethanol.
  • alcohol such as ethanol
  • the aspect of the alcohol treatment step is not particularly limited.
  • the extraction step using an alcohol-based solvent such as ethanol corresponds to the alcohol treatment step, and typically, the antiviral use of the present invention.
  • alcohol can be added to the oyster extract that has been subjected to the above heat treatment, if necessary, and mixed.
  • Such alcohol treatment also has an effect of sterilizing miscellaneous bacteria contained in the oyster extract itself.
  • the oyster extract of the present invention is solidified by concentration, drying, or freeze-drying as necessary, in addition to the above-mentioned treatment, or in addition to the above-mentioned treatment, as long as the effects of the invention are not impaired.
  • pulverization freeze-dried powder is usually slightly yellow
  • purification using an ion exchange resin or the like may be performed.
  • the oyster extract contains a large amount of polyphenol, and if it remains in a liquid state, it tends to undergo coloration and other alterations. Therefore, it is desirable that the oyster extract be stored frozen in a solid state using a freeze-drying method. These operations are preferably performed under mild conditions such that oyster tannin and other components contained in the oyster extract are not decomposed.
  • the oyster extract in the present invention is a liquid obtained by squeezing immature astringency and then fermenting and aging for a long time (about 1 to 3 years), and has a solid content of about several percent (oyster tannin). ) And organic acid produced by fermentation or the like may be used.
  • this persimmon has been used as a folk medicine or paint, and is generally marketed as a product such as “Tsubaki Shibu” (Takeyama Shibu Production Center).
  • a fermentation product obtained by adding an oyster-derived yeast culture solution to oyster juice and fermenting it at 20-25 ° C. for 1 to 3 months can be used (usually a reddish brown solution). It is preferable to store within.
  • Basic, manufacturing method, essence Oyster oyster Diospyros kaki THUNB.
  • the main components are tannin and tannic acid.
  • the additive described as oyster extract in the present invention is used. You can also
  • tannins Plants of the genus Diospyros, especially their fruits, are generically called so-called tannins, which have certain properties, such as astringency and binding to metal ions, that make them feel astringent. Rich in compounds.
  • Such oyster tannins often contain “oyster condensed tannin” represented by the following estimated structural formula (I), which is formed by binding catechin, gallocatechin and gallate esters thereof as a main component. It is characteristic that it is.
  • Oyster condensed tannins contained in the fruit of Diospyros kaki, native to Japan and widely cultivated worldwide are catechin, catechin gallate, gallocatechin and gallocatechin. It is a polymer compound in which gallate is condensed with a carbon-carbon bond at a ratio of about 1: 1: 2: 2 (see Matsuo & Itoo (1981a): Non-Patent Document 1 above).
  • oyster tannins may contain other tannic compounds such as catechins and hydrolyzable tannins in addition to the above “oyster condensed tannins”.
  • Hydrolyzed tannin is an ester of an alcohol (such as glucose) and a carboxylic acid (such as gallic acid) or an oligomer thereof, and its molecular weight is reduced by hydrolysis, whereas oyster condensed tannin is hydrolyzed. It can be distinguished from hydrolyzed tannins because it does not reduce the molecular weight (the carbon-carbon bond of the basic skeleton of the polymer is not hydrolyzed), and is described in, for example, Matsuo & Itoo (1981b) (Non-Patent Document 2). It is also possible to purify and quantify by a method that has been developed.
  • oyster condensed tannin is contained in the oyster extract, but the contribution of other components in the oyster extract The possibility of is not excluded at all.
  • the oyster extract obtained by the preparation method as described later using oyster fruit usually contains oyster condensed tannin, and the antiviral agent of the present invention uses such an oyster extract. It is presumed that it is preferable to use it as a raw material.
  • the antiviral agent of the present invention includes influenza A virus genus (human influenza virus, avian influenza virus, etc.), vesiculovirus genus (vesicular stomatitis virus, etc.), simple virus genus (herpes simplex virus type 1) Etc.), catechins can also be used as active ingredients when targeting envelope viruses such as the genus Aburavirus (Newcastle disease virus etc.), Nobilabd virus genus (virus hemorrhagic sepsis virus etc.).
  • influenza A virus genus human influenza virus, avian influenza virus, etc.
  • vesiculovirus genus vesicular stomatitis virus, etc.
  • simple virus genus herpes simplex virus type 1 Etc.
  • catechins can also be used as active ingredients when targeting envelope viruses such as the genus Aburavirus (Newcastle disease virus etc.), Nobilabd virus genus (virus hemorrhagic sepsis virus etc.).
  • Catechins are contained in plants such as catechu (also known as gan beer, scientific name Acacia catechu) and tea tree (tea tree, scientific name: Camellia sinensis), which are shrubs of the leguminous acacia genus from India. 7,3 ′, 4′-pentahydroxyflavan (catechin in the narrow sense), 3,5,7,3 ′, 4 ′, 5′-hexahydroxyflavan (gallocatechin) and their 3-galloyl derivatives, These stereoisomers are also included.
  • (+)-catechin separated from catechu has the following structural formula (2).
  • catechins (sometimes referred to as “green tea tannin”) contained in tea tree are epicatechin [epicatechin, structural formula (3)] and its epigallocatechin [epigallocatechin, structural formula (4) )], And their gallic esters, epicatechin gallate [epicatechin gallate, structural formula (5)] and epigallocatechin gallate [epigallocatechin gallate, structural formula (6)], which are heated. It may be isomerized by treatment.
  • Catechins are also contained in other plants.
  • these compounds may be isolated and used from a plant containing catechins, or an extract of a plant containing catechins may be used.
  • any one catechin may be used alone, or two or more catechins may be used in combination. It is most convenient to use catechins contained in chanoki.
  • the antiviral agent of the present invention includes influenza A virus genus (human influenza virus, avian influenza virus, etc.), becyclovirus genus (vesicular stomatitis virus, etc.), simple virus genus (herpes simplex virus 1) Type), Avuravirus genus (Newcastle disease virus, etc.), Nobilabd virus genus (viral hemorrhagic septic virus, etc.), etc., it is also possible to use Watrutannin as an active ingredient it can.
  • influenza A virus genus human influenza virus, avian influenza virus, etc.
  • becyclovirus genus vesicular stomatitis virus, etc.
  • simple virus genus (herpes simplex virus 1) Type)
  • Avuravirus genus Newcastle disease virus, etc.
  • Nobilabd virus genus viral hemorrhagic septic virus, etc.
  • Watru tannin is a tannin extracted from the bark, leaves, cocoons, etc. of plants of the genus Acacia. ), Derived from Acacia mearnsii (Black Wattle).
  • the antiviral agent of the present invention includes influenza A virus genus (human influenza virus, avian influenza virus, etc.), simple virus genus (herpes simplex virus type 1 etc.), abular virus genus (Newcastle disease)
  • influenza A virus genus human influenza virus, avian influenza virus, etc.
  • simple virus genus simplex virus type 1 etc.
  • abular virus genus Newcastle disease
  • envelope viruses such as viruses and the like
  • nobirabradoviruses such as viral hemorrhagic septic virus
  • pentagalloylglucose can also be used as an active ingredient.
  • Pentagalloyl glucose is a compound in which gallic acid is ester-bonded to hydroxyl groups (1, 2, 3, 4, and 6 positions) of glucose, and can be obtained, for example, by decomposing and purifying pentaploid tannin as a raw material.
  • coffee tannin can also be used as an active ingredient.
  • an envelope virus such as Nobilabdovirus genus (such as viral hemorrhagic septic virus)
  • coffee tannin can also be used as an active ingredient.
  • Coffee tannins are tannins (or tannin-like substances) extracted from coffee beans, etc., and mainly caffeic acid esterified with chlorogenic acids (hydroxyl groups of quinic acid (any one or more of the 3, 4 or 5 positions)). Compound).
  • ⁇ Pyrogallol Antiviral agent of the present invention includes influenza A virus genus (human influenza virus, avian influenza virus, etc.), becyclovirus genus (vesicular stomatitis virus, etc.), simple virus genus (herpes simplex virus type 1 etc.)
  • influenza A virus genus human influenza virus, avian influenza virus, etc.
  • becyclovirus genus vesicular stomatitis virus, etc.
  • simple virus genus herpes simplex virus type 1 etc.
  • envelope viruses such as Nobirabridovirus (such as viral hemorrhagic sepsis virus)
  • pyrogallol (1,2,3-trihydroxybenzene) can also be used as an active ingredient.
  • gallic acid can also be used as an active ingredient.
  • the antiviral agent of the present invention targets an envelope virus such as Nobilabdovirus genus (viral hemorrhagic septic virus, etc.)
  • the active ingredient is pentaploid tannin, which is derived from a quintuplet (nulde bug hump). Can also be used.
  • the antiviral agent of the present invention is an influenza A virus genus (human influenza virus, avian influenza virus, etc.), vesiculovirus genus (vesicular stomatitis virus, etc.), simple virus genus ( When targeting envelope viruses such as herpes simplex virus type 1), novirabdovirus (virus hemorrhagic septic virus, etc.), organic acids and / or salts other than those contained in oyster extracts It can also be used as an active ingredient.
  • influenza A virus genus human influenza virus, avian influenza virus, etc.
  • vesiculovirus genus vesicular stomatitis virus, etc.
  • simple virus genus When targeting envelope viruses such as herpes simplex virus type 1), novirabdovirus (virus hemorrhagic septic virus, etc.), organic acids and / or salts other than those contained in oyster extracts It can also be used as an active ingredient.
  • Organic acids and / or their salts are excellent in antibacterial properties against bacteria and are also recognized as food additives.
  • coloring when tannin comes into contact with iron also acts as a chelating agent to prevent From such a viewpoint, it is also preferable to add an organic acid and / or a salt thereof to the antiviral composition of the present invention.
  • the organic acid and / or salt thereof is preferably an organic acid having 2 to 10 carbon atoms and / or a salt thereof, and more preferably an organic acid containing a hydroxyl group having 2 to 10 carbon atoms and / or a salt thereof. More specifically, at least one organic acid selected from the group consisting of lactic acid, malic acid, citric acid, tartaric acid, salicylic acid, succinic acid, fumaric acid and itaconic acid and / or a salt thereof is preferable. Or its salt is preferable. Moreover, as a salt of an organic acid, the sodium salt of the said organic acid, potassium salt, etc. are preferable.
  • the organic acid and / or a salt thereof is added to the antiviral composition of the present invention as an active ingredient for a specific envelope virus and / or for other purposes as described above, the organic acid and / or its The proportion of the salt is preferably 0.05 to 5.0% by weight, more preferably 0.1 to 2.0% by weight, based on the entire antiviral composition (including the solvent and the like).
  • the pH of the antiviral composition is usually 6.0 to 2.0, preferably 5.0 to 2.0, more preferably 4.8 to 2.0. And more preferably in an amount of 4.0 to 2.0.
  • the pH of the aqueous solution may be measured using a general pH meter (for example, a pH meter manufactured by Beckman Coulter, Inc.).
  • an antiviral agent containing an organic acid and / or a salt thereof as an active ingredient when used alone, it is preferable to adjust the pH of the antiviral agent itself within the above range, but the antiviral agent is an antiviral composition.
  • the pH of the antiviral agent itself is adjusted in advance to be lower than the above range as necessary so that the final pH of the composition falls within the above preferable range. You may keep it.
  • the antiviral composition of the present invention contains an antiviral agent as an active ingredient against an enveloped virus, and at least one component of alcohol, surfactant, antibacterial agent, moisturizing agent, and cosmetic oils and fats. If necessary, the composition further contains citric acid and / or a salt thereof and vitamin C. Although the aspect is not specifically limited, The following are mentioned typically.
  • composition of the aspect which can disinfect the virus and disinfect the envelope virus is provided as a liquid or solid detergent, for example.
  • Alcohol preparations and disinfecting compositions are free of enveloped viruses and bacteria adhering to food, tableware, cooking utensils, fish and other breeding equipment, fish tanks, workers' hands, or patients handling filth.
  • These cleaning compositions or disinfecting compositions can also be in a mode for disinfecting viruses such as fish, eggs, larvae or parent fish.
  • Lotions, creams and milky lotions are compositions (basic cosmetics) that can be applied to the fingers of workers who are easily roughened by water work to provide skin care and disinfect envelope viruses.
  • the alcohol, surfactant, antibacterial agent, moisturizing agent, and cosmetic fats and oils may naturally be used in combination of two or more.
  • a surfactant such as a fatty acid ester
  • the cleaning composition can take a form such as a hand soap containing an antibacterial agent or an alcohol in addition to a surfactant, and the cream keeps the hand skin clean with components for protecting the hand skin. Therefore, it is possible to take an aspect in which an antibacterial agent or alcohol is added.
  • the antiviral composition of the present invention may be provided with various components, such as an increase in a desired performance and a quality of each composition.
  • a cosmetic such as a viscous agent (xanthan gum, locust bean gum, sodium polyacrylate, etc.), an antioxidant, a fragrance, a pigment, or a lotion, a rough skin preventing agent, an anti-inflammatory agent, and the like can be appropriately blended.
  • the content of the antiviral agent in the antiviral composition of the present invention depends on the compositional composition, usage method, etc., as long as antiviral properties against the envelope virus are expressed.
  • the antiviral agent, more specifically, the active ingredient such as oyster extract in the antiviral agent is preferably 0.01 to 5% by weight based on the whole antiviral composition. More preferably, the amount may be 0.1 to 2% by weight.
  • the content of the above-mentioned antiviral agent is based on the “solid content”.
  • a liquid material such as an extract of persimmon fruit
  • the solid content dried in the liquid material
  • the blending amount of the liquid material may be adjusted so that the weight of the powder obtained by freeze-drying is within the above range.
  • Persimmon fruit juice usually contains about 5-10% solids.
  • vitamin C is a general term including DL-ascorbic acid, ascorbic acid ester (such as palmitic acid ester) and the like in addition to L-ascorbic acid generally called vitamin C.
  • the amount of vitamin C added is preferably 0.01 to 5.0% by weight, preferably 0.05 to 2.0% by weight, based on the whole antiviral composition (including solvent and the like). Is more preferable.
  • Alcohol the same alcohol as that used in general alcohol preparations can be used, but ethanol and / or propanol which have excellent antibacterial properties against bacteria and are recognized as food additives are preferable.
  • concentration of these alcohols may be about the same as that of a general alcohol preparation and can be adjusted in consideration of antibacterial properties, but is preferably about 10 to 80% with respect to the whole alcohol preparation.
  • Alcohol may be used as a solvent in a composition other than an alcohol preparation, and may be blended in cosmetics or the like as a component that provides astringency and antiseptic properties to the skin.
  • Surfactant include cationic, anionic, zwitterionic and nonionic surfactants.
  • anionic surfactants it is preferable to use a surfactant and / or a nonionic surfactant.
  • anionic surfactant examples include soap (alkali salt of higher fatty acid), monoalkyl sulfate, alkyl polyoxyethylene sulfate, alkyl benzene sulfonate, monoalkyl phosphate, and the like.
  • nonionic surfactants include polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, fatty acid partial esters of polyhydric alcohols (such as glycerin and sugar alcohol), and fatty acid diethanolamides.
  • surfactants those recognized as food additives such as glycerin fatty acid partial ester, sorbitan fatty acid partial ester, and sucrose fatty acid partial ester do not pose a problem even if they adhere to food, tableware or cooking utensils. Therefore, it is a preferable surfactant in the present invention.
  • the surfactants described above also have an action of destroying bacterial cell membranes and viral envelopes.
  • partial esters of glycerin with fatty acids having 6 to 18 carbon atoms (capric acid having 10 carbon atoms, etc.) Because of its excellent antiviral properties against enveloped viruses and antibacterial properties against Escherichia coli and Staphylococcus aureus, it is also suitable to incorporate these surfactants as active ingredients in the aforementioned antiviral agents or in compositions such as alcohol preparations. It is.
  • the surfactant is also used as a component for mixing the oil phase and the aqueous phase in creams and emulsions.
  • Antibacterial agents include substances called bactericides and disinfectants
  • other than the aforementioned organic acids such as ethanol and citric acid and salts thereof that can be used in the present invention are not particularly limited.
  • antibiotics and synthetic antibacterial agents such as Escherichia coli, Staphylococcus aureus, MRSA, Salmonella, Vibrio parahaemolyticus, Pseudomonas aeruginosa, etc. Those are preferred.
  • synthetic antibacterial agents such as isopropylmethylphenol, butyl parahydroxybenzoate, and triclosan are preferable antibacterial agents in the present invention in terms of excellent antibacterial action and compatibility with oyster extract.
  • the substance used as an antibacterial agent as described above may be blended in the ethanol preparation described above, and may be used as a preservative in cosmetics and the like.
  • the moisturizer (humectant) that can be used in the present invention is the same as that used in cosmetics such as general lotions, emulsions, creams, etc., for example, glycerin, propylene glycol, sorbitol, polyethylene Examples include glycol, hyaluronic acid, sodium chondroitin sulfate, ceramide, and aloe extract.
  • humectants those recognized as foods or food additives such as aloe extract are preferred humectants in the present invention in that they do not pose a problem even if they adhere to foods, tableware, and cooking utensils.
  • Cosmetic oils and fats form a film on the skin surface to play a role in protecting the skin, providing flexibility and lubricity, and providing cosmetics with an appropriate feeling of use. It is.
  • cosmetic oils and fats similar to those used in general cosmetics such as emulsions and creams can be used, and examples thereof include the following.
  • Fats and oils esters of higher fatty acids and glycerin
  • vegetable oils, animal fats and oils or hydrogenated products thereof partially hydrogenated rapeseed oil, etc.
  • synthetic triglycerides tri (capryl / capric acid) glyceryl, etc.
  • Wax esters of higher fatty acids and higher alcohols that are solid at room temperature
  • vegetable wax, animal wax eg, beeswax, lanolin, etc.
  • Hydrocarbons mineral hydrocarbons (liquid paraffin, petrolatum, paraffin, etc.), animal hydrocarbons (squalane, etc.)
  • ⁇ Higher fatty acids Lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, isostearic acid, etc .
  • ⁇ Higher alcohol cetanol, stearyl alcohol, lanolin alcohol, etc .
  • Esters esters of fatty acids and alcohols other than waxes):
  • cosmetic oils and fats those recognized as foods or food additives such as beeswax are preferable cosmetic oils and fats in the present invention in that they do not pose a problem even if they adhere to foods, tableware, and cooking utensils. .
  • the manufacturing method of the composition for anti-viruses of this invention mix
  • blends an antiviral agent as one of the manufacturing raw materials
  • blends vitamin C as needed
  • an antiviral agent and other ingredients are added to purified water to prepare an aqueous phase part, while an oil phase part composed of cosmetic fats and oils is prepared. What is necessary is just to manufacture so that it may mix in a predetermined ratio.
  • the method of using the antiviral composition of the present invention is the same as that for conventional alcohol preparations, cleaning agents, disinfectants, lotions, emulsions, creams and the like.
  • it may be a concentrated type that is diluted when used, or if it is an alcohol preparation or disinfectant, in addition to a spray type, it may be impregnated into a non-woven fabric to be a wiping type.
  • the antiviral composition of the present invention can be appropriately commercialized in a preferable mode depending on the method of use.
  • the pH of the aqueous solution is preferably 5.0 to 2.0, more preferably 4.8. It is preferable to add an organic acid and / or a salt thereof in an amount of -2.0, more preferably 4.0-2.0.
  • -Pharmaceuticals The antiviral agent of the present invention can be used as an active ingredient of a therapeutic or prophylactic agent for infectious diseases caused by enveloped viruses.
  • Such pharmaceutical dosage forms can be appropriately selected from, for example, oral ingestion types such as liquids, syrups, tablets, capsules, powders, granules, and injections, and excipients as necessary.
  • lactose and other sugars For example, lactose and other sugars
  • binders for example, starch, methylcellulose, polyvinyl alcohol
  • stabilizers for example, ascorbic acid
  • preservatives for example, paraoxybenzoic acid esters
  • sweeteners solvents, and other various additives.
  • the effective dosage of these pharmaceuticals can be appropriately determined according to the patient's age, weight, symptoms, route of drug administration, administration schedule, formulation form, strength of inhibitory activity of the material, etc. What is necessary is just to adjust content of these antiviral agents according to those conditions.
  • the antiviral agent of this invention and the pharmaceutical containing this can take not only the aspect administered to a human but the aspect administered to animals other than a human which can be infected with envelope viruses, such as mammals and fish.
  • envelope viruses such as mammals and fish.
  • an antiviral agent or a medicine containing it can be mixed with the feed and administered orally, or by forced oral administration using a syringe or the like, or an antiviral agent added to the breeding water
  • a method such as “medicine bath” where fish are kept for a certain time or at all times.
  • the antiviral agent of the present invention may be used, for example, as a gargle or an oral spray after being diluted with water to an appropriate concentration, and its use is not particularly limited.
  • Example 1 A drug according to the composition shown in Table 2 was prepared, and human influenza virus, avian influenza virus, and vesicular stomatitis virus were diluted as they were, and herpes simplex virus type 1 and Newcastle disease virus were further diluted in half with water.
  • PBS phosphate buffered saline
  • persimmon astringent FD powder is sterilized by cutting the immature fruit of the persimmon that has been thoroughly sterilized (NaClO), washed, discoloration-prevented (vitamin C), etc.
  • the obtained fruit / fruit juice solution was passed through a 200 mesh sieve, centrifuged, subjected to high-temperature sterilization (120 to 130 ° C., 7 to 10 seconds), and then freeze-dried and used.
  • the virus solution of each test virus shown in Table 3 above and each drug or control shown in Table 2 above were mixed in an equivalent amount (35 ⁇ L each) and reacted at room temperature for 3 minutes, and then DMEMD (Sulbecco's modified minimun Essential dilution medium) was used to prepare a 10-fold serial dilution series.
  • the diluted virus solution was inoculated into a monolayer culture cell of a 96-well plate (100 ⁇ L / well) and cultured. After 4 days, the CPE spread and fixed and stained, and the Behrens-Kaerber method was used to calculate the 50% infectious dose (unit: 50% tissue culture infections dose [TCID50]), and the virus infectivity titer was measured. The results are as shown in Table 4 and FIGS.
  • pentagalloylglucose was somewhat weak against vesicular stomatitis virus, antiviral activity against each virus was confirmed. Pyrogallol was also confirmed to have antiviral activity against four types of viruses except Newcastle disease virus. Furthermore, glycerin monocaprate was confirmed to have antiviral activity against all of the above five viruses, and citric acid / trisodium citrate was confirmed to have antiviral activity against four viruses excluding Newcastle disease virus.
  • coffee tannin showed almost no antiviral activity against any of the above five viruses.
  • Propyl gallate showed some antiviral activity depending on the type of virus.
  • VHSV Viral hemorrhagic septic virus
  • test reagents are shown in Table 5. Each test reagent was adjusted to a concentration of 0.2% using Hanks' balanced salt solution (Nissui) (HBSS). To 50 ⁇ L of the reagent, 50 ⁇ L of various virus solutions were mixed (final reagent concentration 0.1%) and allowed to stand at room temperature for 2 minutes. Thereafter, the reaction was stopped by adding 9.9 mL HBSS, and a 10-fold dilution series of these samples was prepared using HBSS.
  • HBSS Hanks' balanced salt solution
  • FHM fish cultured cells (derived from Pimephales® promelas) were seeded in a 96-well plate (IWAKI) to 80% confluent, and 90 ⁇ L of the medium was added to each well and cultured for 24 hours.
  • the medium used was MEM.
  • 10 ⁇ L of the previously prepared dilution series solution was inoculated into each well and further cultured for 10 days to confirm the appearance of cytopathic effect (indicator of virus infection).
  • the limiting dilution point at which no cytopathic effect was observed was confirmed, and the virus titer was measured according to the method of Reed and Muench (1938).
  • the ratio of the virus titer of the test group to the virus titer (100%) of the control group was calculated to evaluate the antiviral activity (Table 6).
  • fermented koji juice oyster extract
  • pentagalloyl glucose wattle tannin
  • green tea tannin catechins
  • pyrogallol a certain effect
  • Example 3 By mixing the following ingredients with stirring, an ethanol preparation, a hand-washing foam and a hand lotion could be prepared.
  • Ethanol preparation (HA-72A): Kojibu FD powder 0.3 parts by weight / ethanol 50 parts by weight / citric acid 1.6 parts by weight / trisodium citrate 0.5% by weight / glycerin monocaprate 0.5 parts by weight / Water (remainder).
  • Ethanol preparation 0.3 parts by weight of strawberry astringent FD / 50 parts by weight of ethanol / 1.6 parts by weight of citric acid / 0.5 parts by weight of trisodium citrate / 0.5 parts by weight of glycerin monocaprate / 0.5% by weight of vitamin C Parts / water (remainder).
  • Hand-washing foam 0.1 parts by weight of isopropylmethylphenol / 0.5 parts by weight of persimmon FD powder / 20 parts by weight of 95% ethanol / Mydol 12 (manufactured by Kao Corporation. 7.0 parts by weight of lauryl glucoside) / 15 glycerin 0.0 part by weight / 1.0 part by weight of citric acid / 0.3 part by weight of glycerol monocaprate / 56.1 parts by weight of purified water.
  • Hand-washing foam (KSF15-2): 0.1 parts by weight of isopropylmethylphenol / 0.5 parts by weight of persimmon FD powder / 18 parts by weight of 95% ethanol / Mydol 12 (produced by Kao Corporation. Lauryl glucoside) 7.0 Parts by weight / glycerin 15.0 parts by weight / citric acid 1.0 part by weight / glycerin monocaprate 0.3 part by weight / purified water 58.1 parts by weight.
  • Hand lotion Allantoin 0.1 part by weight / Dipotassium glycyrrhizinate 0.1 part by weight / Ashibu Shibu FD powder 0.3 part by weight / 95% ethanol 54.0 part by weight / Glycerin 2.0 part by weight / Citric acid 0.7 Parts by weight / trisodium citrate 0.3 parts by weight / glycerin monocaprate 0.3 parts by weight / purified water 42.0 parts by weight.
  • Example 4 (1) Agents used HA-72A and KSF15-2 prepared according to Example 3, and phosphate buffered saline (PBS) as a control (2) Virus used Avian influenza virus A / swan / Shimane / 499/83 (H5N3) (3) Cells MDCK (+) cells (Canine renal tubular epithelial cell origin: Noma K et al. Arch. Virol. 143: 1893-1909, 1998.) (4) Virus infectivity titration method Equal volumes of virus solution and drug (35 ⁇ L each) were mixed, reacted at room temperature for 3 minutes, and 10-fold serial dilutions were prepared with DMEM (Dulbecco's modified minimum essential medium). .
  • PBS phosphate buffered saline
  • the diluted virus solution was inoculated into a monolayer culture cell of a 96-well plate (100 ⁇ L / well) and cultured. After 4 days, when the CPE spread, the cells were fixed and stained, the 50% infectious dose (unit: 50% tissue culture infectious dose [TCID50]) was calculated using the Behrens-Kaerber method, and the virus infectivity titer was measured.
  • 50% infectious dose unit: 50% tissue culture infectious dose [TCID50]
  • the virus solution and the drug were mixed, and after a predetermined time (10, 30, 30 seconds), diluted with DMEM 500 times to stop the reaction with the drug. was measured.
  • the obtained infectious titer was corrected by multiplying by 500 tons.
  • Example 5 (1) Agents used HA-72A and KSF15-2 prepared according to Example 3, and phosphate buffered saline (PBS) as a control (2) Viruses and cells used
  • Example 6 (1) Manufacturing method of aqueous juice liquid After washing and drying 330 g of raw material blue koji (chiba prefecture Chimoku rice, collected on August 22, 2009) to remove koji, the seeds were removed at the same time as cutting to about 2 cm square. (280 g). This was taken in a mixer and ground sufficiently with 2.8 g (1%) of L-ascorbic acid (vitamin C) and 280 ml of purified water over about 3 minutes. This was squeezed several times with a non-woven fabric and sterilized by heating at 70-80 ° C. for about 30 minutes to obtain a pale yellow liquid (460 g). When this aqueous squeezed juice (processed oyster extract) was placed in a sealed container and placed at room temperature, it could be stored for a long period (at least 3 months) without producing off-flavors, discoloration, or precipitation.
  • aqueous squeezed juice processed oyster extract

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un agent antiviral ayant une excellente efficacité contre des virus enveloppés et très sûr pour les corps humains. L'invention porte également sur une composition antivirale contenant l'agent antiviral et utile pour l'éradication des virus ou pour la prévention d'une infection virale. L'agent antiviral est caractérisé en ce qu'il comprend, en tant qu'ingrédient actif, une matière traitée extraite du kaki, produite par chauffage d'un jus pressé contenant du tanin ou extrait d'un fruit d'une plante Diospyros, ou par traitement du jus pressé contenant du tanin ou extrait par un alcool pour désactiver une enzyme issue de la plante Diospyros et contenue dans le jus pressé ou l'extrait. La composition antivirale est caractérisée en ce qu'elle comprend l'agent antiviral et un alcool, un agent tensio-actif ou un agent antibactérien. De préférence, la composition antivirale contient en plus de la vitamine C.
PCT/JP2009/070764 2008-12-12 2009-12-11 Agent antiviral et composition antivirale WO2010067869A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010542138A JP5670201B2 (ja) 2008-12-12 2009-12-11 Ａ型インフルエンザウイルス属のエンベロープウイルスに対する抗ウイルス剤および抗ウイルス用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008316901 2008-12-12
JP2008-316901 2008-12-12

Publications (1)

Publication Number Publication Date
WO2010067869A1 true WO2010067869A1 (fr) 2010-06-17

Family

ID=42242854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/070764 WO2010067869A1 (fr) 2008-12-12 2009-12-11 Agent antiviral et composition antivirale

Country Status (2)

Country Link
JP (1) JP5670201B2 (fr)
WO (1) WO2010067869A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011084549A (ja) * 2009-10-16 2011-04-28 Woongjin Coway Co Ltd タンニン酸を含むインフルエンザウイルス感染の予防用組成物、該組成物を含むエアフィルター、及び該フィルターを含む空気清浄器
JP2013014568A (ja) * 2011-07-06 2013-01-24 Georgia Health Sciences Univ Research Inst Inc 単純ヘルペスウイルスを処置するための組成物および方法
JP2013087101A (ja) * 2011-10-20 2013-05-13 Hiroshima Univ カリン等抽出物を有効成分とする非エンベロープウイルスに対する抗ウイルス剤
JP2013087102A (ja) * 2011-10-20 2013-05-13 Hiroshima Univ バナナ等抽出物を有効成分とする非エンベロープウイルスに対する抗ウイルス剤
US8603227B2 (en) 2009-10-16 2013-12-10 Woongjin Coway Co., Ltd. Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter
JP2013249263A (ja) * 2012-05-30 2013-12-12 Ajinomoto Co Inc ガロタンニン含有組成物
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
JP2016222736A (ja) * 2016-10-05 2016-12-28 味の素株式会社 ガロタンニン含有組成物
JPWO2015072125A1 (ja) * 2013-11-14 2017-03-16 日本曹達株式会社 抗パルボウイルス組成物
JP2019089732A (ja) * 2017-11-15 2019-06-13 出光興産株式会社 薬剤、その使用方法及び製造方法
JP2021066728A (ja) * 2019-10-25 2021-04-30 揚州大学Ｙａｎｇｚｈｏｕ Ｕｎｉｖｅｒｓｉｔｙ 偽狂犬病ウイルス（ｐｒｖ）感染の予防及び／または治療製剤の調製におけるｅｇｃｇの応用、偽狂犬病ウイルス（ｐｒｖ）感染の予防及び／または治療製剤
JP6960707B1 (ja) * 2021-01-18 2021-11-05 リリース科学工業株式会社 新型コロナウイルス不活性化剤
WO2022153572A1 (fr) * 2021-01-18 2022-07-21 リリース科学工業株式会社 Inhibiteur d'infection au nouveau coronavirus
WO2022224464A1 (fr) * 2021-04-21 2022-10-27 順也 藤森 Composition phytochimique
CN115487170A (zh) * 2022-11-04 2022-12-20 高州市人民医院 连苯三酚在制备预防或治疗流感病毒感染药物中的应用
CN118477065A (zh) * 2024-05-14 2024-08-13 南阳师范学院 表没食子儿茶素没食子酸酯在抗大口黑鲈弹状病毒方面的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59128329A (ja) * 1983-01-07 1984-07-24 Yasuo Tanaka 抗ウィルス剤
JPS60202826A (ja) * 1984-03-26 1985-10-14 Sankyo Co Ltd ミズカビ着生防止剤
JP2004065174A (ja) * 2002-08-08 2004-03-04 Niigata Prefecture 柿渋の製造方法
WO2007080669A1 (fr) * 2006-01-11 2007-07-19 Microbiotech Inc. Composition medicamenteuse antivirale/anti-inflammatoire

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59128329A (ja) * 1983-01-07 1984-07-24 Yasuo Tanaka 抗ウィルス剤
JPS60202826A (ja) * 1984-03-26 1985-10-14 Sankyo Co Ltd ミズカビ着生防止剤
JP2004065174A (ja) * 2002-08-08 2004-03-04 Niigata Prefecture 柿渋の製造方法
WO2007080669A1 (fr) * 2006-01-11 2007-07-19 Microbiotech Inc. Composition medicamenteuse antivirale/anti-inflammatoire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAI 56 KAI THE JAPANESE SOCIETY OF VIROLOGY GAKUJUTSU SHUKAI PROGRAM-SHOROKU-SHU, 1 October 2008 (2008-10-01), pages 344 - 1P136 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
JP2011084549A (ja) * 2009-10-16 2011-04-28 Woongjin Coway Co Ltd タンニン酸を含むインフルエンザウイルス感染の予防用組成物、該組成物を含むエアフィルター、及び該フィルターを含む空気清浄器
US8603227B2 (en) 2009-10-16 2013-12-10 Woongjin Coway Co., Ltd. Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter
JP2013014568A (ja) * 2011-07-06 2013-01-24 Georgia Health Sciences Univ Research Inst Inc 単純ヘルペスウイルスを処置するための組成物および方法
JP2013087101A (ja) * 2011-10-20 2013-05-13 Hiroshima Univ カリン等抽出物を有効成分とする非エンベロープウイルスに対する抗ウイルス剤
JP2013087102A (ja) * 2011-10-20 2013-05-13 Hiroshima Univ バナナ等抽出物を有効成分とする非エンベロープウイルスに対する抗ウイルス剤
JP2013249263A (ja) * 2012-05-30 2013-12-12 Ajinomoto Co Inc ガロタンニン含有組成物
JPWO2015072125A1 (ja) * 2013-11-14 2017-03-16 日本曹達株式会社 抗パルボウイルス組成物
JP2016222736A (ja) * 2016-10-05 2016-12-28 味の素株式会社 ガロタンニン含有組成物
JP2019089732A (ja) * 2017-11-15 2019-06-13 出光興産株式会社 薬剤、その使用方法及び製造方法
JP6997440B2 (ja) 2017-11-15 2022-02-21 国立大学法人北海道大学 薬剤、その使用方法及び製造方法
JP2021066728A (ja) * 2019-10-25 2021-04-30 揚州大学Ｙａｎｇｚｈｏｕ Ｕｎｉｖｅｒｓｉｔｙ 偽狂犬病ウイルス（ｐｒｖ）感染の予防及び／または治療製剤の調製におけるｅｇｃｇの応用、偽狂犬病ウイルス（ｐｒｖ）感染の予防及び／または治療製剤
JP7014463B2 (ja) 2019-10-25 2022-02-01 揚州大学 偽狂犬病ウイルス（ｐｒｖ）感染の予防及び／または治療製剤
JP6960707B1 (ja) * 2021-01-18 2021-11-05 リリース科学工業株式会社 新型コロナウイルス不活性化剤
WO2022153572A1 (fr) * 2021-01-18 2022-07-21 リリース科学工業株式会社 Inhibiteur d'infection au nouveau coronavirus
WO2022224464A1 (fr) * 2021-04-21 2022-10-27 順也 藤森 Composition phytochimique
JP7611783B2 (ja) 2021-04-21 2025-01-10 順也 藤森 フィトケミカル組成物の製造方法
CN115487170A (zh) * 2022-11-04 2022-12-20 高州市人民医院 连苯三酚在制备预防或治疗流感病毒感染药物中的应用
CN118477065A (zh) * 2024-05-14 2024-08-13 南阳师范学院 表没食子儿茶素没食子酸酯在抗大口黑鲈弹状病毒方面的应用

Also Published As

Publication number Publication date
JPWO2010067869A1 (ja) 2012-05-24
JP5670201B2 (ja) 2015-02-18

Similar Documents

Publication Publication Date Title
JP5670201B2 (ja) Ａ型インフルエンザウイルス属のエンベロープウイルスに対する抗ウイルス剤および抗ウイルス用組成物
JP5421901B2 (ja) エンテロウイルス属の非エンベロープウイルスに対する抗ウイルス剤および抗ウイルス用組成物
JP5092145B2 (ja) 抗ノロウイルス剤およびこれを含有する組成物
JP5571577B2 (ja) Ａ型インフルエンザウイルス属のエンベロープウイルスに対する抗ウイルス性衛生用繊維製品
JP2007119373A (ja) メイラード反応生成物分解剤およびそれを用いた飲食品
JP2003212774A (ja) メイラード反応阻害剤
KR20160079473A (ko) 녹차 추출물을 유효성분으로 포함하여 항바이러스 활성을 가지는 세정 또는 소독용 조성물 제조방법
KR20210016851A (ko) 식물 복합 추출물을 유효성분으로 포함하는 항균 및 소취용 조성물
JP2007204423A (ja) ササ抽出物の製造方法及び該抽出物の利用
JP2006523684A (ja) 活性化かんきつ類果皮エキス含有組成物
KR102171948B1 (ko) 허브 혼합 에센셜 오일을 유효성분으로 함유하는 항균 및 항진균 조성물
KR101928211B1 (ko) 수족구 원인균 엔테로바이러스 71을 포함한 바이러스 및 균에 대해 저해 효과를 갖는 조성물
KR20160079459A (ko) 녹차 추출물을 유효성분으로 포함하여 항바이러스 활성을 가지는 세정 또는 소독용 조성물
KR102411576B1 (ko) 잣나무 잎 추출물을 포함하는 항균 조성물
KR102252009B1 (ko) 비자나무 잎 추출물을 포함하는 항바이러스용 또는 살균용 조성물
JP7175467B2 (ja) ノロウイルスおよびその代替ウイルスに対する抗ウイルス剤および抗ウイルス組成物
JP6975425B2 (ja) 抗ノロウイルス組成物及びその利用
JP6709030B2 (ja) 抗ノロウイルス剤
JP2007131579A (ja) 生理活性組成物及びその製造方法
KR102420990B1 (ko) 잣나무 잎 추출물을 포함하는 항균 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09831972

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2010542138

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09831972

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载